Trial Profile

Anlotinib hydrochloride combined with tirelizumab, paclitaxel liposome and nedaplatin in a single-arm, single-center, phase II exploratory clinical study of preoperative neoadjuvant therapy for esophageal squamous cell carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Tislelizumab (Primary) ; Nedaplatin; Paclitaxel
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

08 Jul 2023 New source identified and integrated Chinese Clinical Trial Register (ChiCTR2100049693).
08 Jul 2023 New trial record
06 Jun 2023 Results reporting efficacy data presented at the 59th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com